Epinephrine Market Size, Share & Industry Analysis, By Product Type (Auto-injectors, Pre-filled Syringes, and Ampoules & Vials), By Application (Anaphylaxis, Cardiac Arrest, Respiratory Disorders, and Others), By Distribution Channel (Hospital Pharmacy and Retail & Online Pharmacy), and Regional Forecast, 2024-2032

The global epinephrine market size was valued at USD 1.92 billion in 2023, and is projected to grow from USD 2.12 billion in 2024 to USD 4.60 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period. North America dominated the global market with a share of 63.54% in 2023. Moreover, the U.S. epinephrine market size is projected to grow significantly, reaching an estimated value of USD 2.81 billion by 2032, driven by Increasing prevalence of cardiac arrest and allergic reactions. 

Epinephrine is used to treat severe allergic reaction anaphylaxis and asthma attacks. It can be administered through various ways including intramuscular, subcutaneous, intravenous, and inhalation. The burden of these diseases have been increasing at a significant rate globally. This has been fueling the demand for epinephrine

• For instance, as per data published by the National Center for Biotechnology Information (NCBI) in 2022, asthma affects around 4.0%-6.0% of adults and 10.0% of the children in Germany.

Furthermore, favorable reimbursement policies and increasing focus of market players on new advanced product launches have also been fueling the market growth.

In 2020, due to the sudden outbreak of COVID-19, the market experienced a decline in its value due to the limited number of patients visits to hospitals and clinics to control the spread of the virus. Moreover, the market players also experienced a decline in the sale of their product offerings.

Epinephrine Market Trends

Emergence of Artificial Intelligence to Enhance Epinephrine’s Drug Delivery

The rising prevalence of medical conditions, such as anaphylaxis, cardiovascular diseases, respiratory diseases (asthma), and others, and the increasing need for effective treatment have been fueling the demand for epinephrine.

• For instance, as per data published by the National Center for Biotechnology Information (NCBI) in 2022, around 20.9% of the population aged 20-44 years suffered from allergic rhinitis in Europe.


• Moreover, according to the National Center for Biotechnology Information (NCBI) in August 2023, more than 50 million Americans suffer from allergies every year.

To control the rising burden of these diseases and allergies, the demand for technologically advanced AI-enabled auto-injectors and needle-free auto-injectors has increased. The increasing applications of these injectors, apart from anaphylaxis in various medical conditions, such as cardiac arrests, respiratory disorders, and other conditions, are creating more opportunities for the key players to launch the product for various conditions.

Additionally, various key players are adopting growth strategies such as acquisition and collaborations to enhance its offerings in the market that will cater to the unmet needs of the patients.

• In November 2021, Marathon Asset Management acquired kaleo, Inc. to enhance the development and commercialization of the company’s offerings.

Epinephrine Market Growth Factors

Growing Prevalence of Asthma and Huge Patient Pool Undergoing Treatment to Support the Demand for Auto-injectors

With the rising prevalence of anaphylaxis and asthma globally, the demand for effective treatment is increasing in developing and developed countries. For instance, as per the Centers for Disease Control and Prevention (CDC), in 2021, around 24.96 million population in the U.S. suffered from asthma.

To cater to this growing demand, major market players are focusing on the introduction of innovative products offering novel routes of administration. These players are now focusing on developing technologically advanced injectors in the market.

• For instance, in July 2022, ARS Pharmaceuticals and Silverback Therapeutics partnered for regulatory approval and commercialization of Neffy, an epinephrine nasal spray.

Additionally, the market players are focusing on increasing the accessibility to its product offerings through acquisitions and partnerships. In November 2021, Kaleo, Inc. and Marathon Asset Management entered an agreement through which Marathon Asset Management acquired Kaleo, Inc. With this acquisition, the company aimed at expanding its offerings focused on anaphylaxis treatment.

Adequate Reimbursement Policies in Developed Countries to Drive the Adoption of Auto-injectors

As the demand for these injections is increasing rapidly in developed countries, such as the U.S. and European countries, companies are focusing on the launch of new products in the market. Moreover, reimbursement policies are improving for these pens as the cost of these auto-injectors is very high and these pens are inaccessible to many patients. For instance, to make these auto-injectors more accessible for patients suffering from anaphylaxis, Medicare offers coverage for the auto-injector through its Part C and Part D drug plans. Part C or the Medicare Advantage (MA) Plan, was established in 2003, whereas the Part D plan came into effect in 2006.

Despite the higher cost of these auto-injectors in developed countries, the penetration is still comparatively higher in these countries. This is due to adequate reimbursement policies available for auto-injectors.

RESTRAINING FACTORS

High Cost of Auto-injectors and Limited Reimbursement in Developing Countries May Limit the Market Growth

With increasing demand for effective treatment options for critical reactions to the allergies such as anaphylaxis, the demand for these injections is increasing rapidly. However, the high cost of auto-injectors is projected to limit the global epinephrine market growth during the forecast period.

• For instance, a set of two EpiPen auto-injectors costs around USD 650 to USD 700. Similarly, Auvi-Q injectable 2 kits of 0.1 mg cost around USD 664.4.

In addition, in developing countries, most people are not aware of the treatment options available for anaphylaxis, this factor has been limiting the adoption of the drug in these countries.

Moreover, lack of reimbursement policies in developing countries and higher out-of-pocket expenditure associated with the auto-injectors are responsible for lower adoption of these products in the market. 

Epinephrine Market Segmentation Analysis

By Product Type Analysis

Various Advantages Associated with the Use of Auto-injectors is Responsible for the Segment’s Dominance

By product type, the market is segmented into auto-injectors, pre-filled syringes, and ampoules & vials.

The auto-injectors segment dominated the market in 2023 owing to the benefits of these auto-injectors over other products such as easy usability, convenient handling, and others. Auto-injectors can be used for emergency treatment of acute anaphylaxis as it helps in fast absorption of the drug. Such factors are responsible for the segment growth.

The pre-filled syringes segment is expected to grow significantly during the forecast period. This is due to its quick response to emergency allergic reactions and increasing demand from hospitals and clinics for the treatment of various illnesses.

By Application Analysis

Increasing Prevalence of Anaphylaxis is Responsible for Dominance of the Segment

On the basis of application, the market is divided into anaphylaxis, cardiac arrest, respiratory disorders, and others.

The anaphylaxis segment dominated the market in 2023, accounting for major global epinephrine market share. The dominance of the segment is attributed to the growing number of cases of anaphylaxis globally. For instance, as per data published by the Centers for Disease Control and Prevention (CDC) in 2021, 25.7% of the adults in the U.S. suffered from seasonal allergy and 6.2% of the adults suffered from food allergy.

The respiratory disorders segment is projected to grow with a significant CAGR during the forecast period. This is due to numerous factors such as rising awareness about the treatment options available for respiratory disorders along with the increasing diagnosis and treatment rate of respiratory disorders.

By Distribution Channel Analysis

Increasing Number of Retail & Online Pharmacy Globally is Responsible for the Segment’s Dominance

On the basis of distribution channel, the market is divided into retail & online pharmacy and hospital pharmacy.

The retail & online pharmacy segment dominated the market in 2023. The factors responsible for the growth of this segment included the increasing number of retail & online pharmacy stores globally, easy presence of auto-injectors, and easy accessibility of the products on the online platforms of the companies.

The hospital pharmacy segment is expected to grow at a substantial CAGR over the forecast period. The increasing emergency hospital visits of the patients due to severe allergic reactions, cardiac arrest, and respiratory conditions, is responsible for the segment’s growth.

REGIONAL INSIGHTS

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The market in North America was valued at USD 1.22 billion in 2023. The region dominated the global market. This is due to various factors such as adequate reimbursement policies in the U.S. for auto-injectors and the increasing launch of technologically advanced products in the market. For instance, in May 2020, kaleo, Inc. announced the availability of ALLERJECT auto-injector in Canada. With this availability, Canadian patients were able to access different treatment options for anaphylaxis.

In Europe, the market growth is due to the increasing prevalence of anaphylaxis, cardiovascular diseases, and others. Moreover, the increasing demand for technologically advanced products in the region is also responsible for the regional growth. For instance, according to an article published in the European Journal of Allergy and Clinical Immunology, in March 2020, the prevalence of food allergies in children from birth to 17 years was around 61.6%.

The Asia Pacific is projected to grow at a significant rate over the forecast period. This is owing to changing regulatory policies for the adoption of auto-injectors. Additionally, companies are expanding their global presence in the region to meet the demand. For instance, in July 2021, ALK-Abelló A/S partnered with Grandpharma to launch its adrenaline auto-injector “Jext” in China. Jext is expected to be the first auto-injector in China.

The market in Latin America is growing due to increasing diagnosis and treatment rate of anaphylaxis, which has created a demand for these injections in the region. The launch of new products is supporting the market growth in the region.

The Middle East & Africa market will expand with a considerable market share during the forecast period. This is due to strategic initiatives taken by governments of various countries to control the increasing prevalence of anaphylaxis.

List of Key Companies in Epinephrine Market

Teva Pharmaceutical Industries Ltd. Leads the Market with Strong Portfolio of Auto-injectors 

The market is consolidated, with a few players holding a major share of the market. Industry leaders, such as Teva Pharmaceutical Industries Ltd., Viatris Inc., and Amneal Pharmaceuticals LLC, are significant players in the market due to the strong sales of their brands, such as EpiPen and EpiPen Jr., among others.

The other market players, such as USWM, LLC., kaleo, Inc., and ALK-Abelló A/S mark a strong global presence. These players have been focusing on partnerships and collaborations to fuel the sale of their products.

• For instance, in August 2022, kaleo, Inc. and Valeo Pharma entered into a ten-year commercialization agreement for ALLERJECT sales in Canada.

LIST OF KEY COMPANIES PROFILED:

• Teva Pharmaceutical Industries Ltd. (Israel)


• Viatris Inc. (U.S.)


• kaleo, Inc. (U.S.)


• Bausch Health Companies Inc. (Canada)


• Amneal Pharmaceuticals LLC. (U.S.)


• USWM, LLC. (U.S.)


• ALK-Abelló A/S (Denmark)

KEY INDUSTRY DEVELOPMENTS:

• December 2023 – Nasus Pharma Ltd, a clinical stage biopharma company, announced the completion of its additional Phase II clinical trial, which confirmed the efficacy and safety of its FMXIN002 Intranasal Epinephrine product.


• March 2023 - Daiichi Sankyo, Inc., through its subsidiary American Regent, Inc., launched sulfite-free Epinephrine Injection, USP, indicated for emergency treatment of type I allergic reaction.


• October 2022 – ARS pharmaceuticals announced that FDA accepted the new drug application for its epinephrine nasal spray, Neffy.


• November 2020 - Upjohn, Pfizer Inc.’s division, and Mylan N.V. formed a global pharmaceutical company called Viatris Inc. The company was formed for product development in therapeutic areas such as cardiovascular diseases, central nervous system and anesthesia, and infectious diseases around the world.


• May 2020 - USWM, LLC. and Adamis Pharmaceuticals Corporation entered an agreement to grant commercial rights to USWM, LLC. for the distribution and commercialization of the SYMJEPI injection.

REPORT COVERAGE

The report provides a detailed market analysis. It focuses on key aspects such as leading companies, product type, applications, and distribution channels. Besides this, it offers insights into the global epinephrine market forecast, market trends, impact of COVID-19, and other key insights. In addition to the factors mentioned above, the report encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 10.2% from 2024-2032
Unit	Value (USD billion)
Segmentation	By Product Type Auto-injectors Pre-filled Syringes Ampoules & Vials
By Application Anaphylaxis Cardiac Arrest Respiratory Disorders Others
By Distribution Channel Hospital Pharmacy Retail & Online Pharmacy
By Region North America (By Product Type, By Application, By Distribution Channel, and By Country) U.S. (By Product Type) Canada (By Product Type) Europe (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region) U.K. (By Product Type) Germany (By Product Type) France (By Product Type) Italy (By Product Type) Spain (By Product Type) Scandinavia (By Product Type) Rest of Europe (By Product Type) Asia Pacific (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region) China (By Product Type) Japan (By Product Type) India (By Product Type) Australia (By Product Type) Southeast Asia (By Product Type) Rest of Asia Pacific (By Product Type) Latin America (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region) Brazil (By Product Type) Mexico (By Product Type) Rest of Latin America (By Product Type) Middle East & Africa (By Product Type, By Application, By Distribution Channel, and By Country/Sub-region) GCC (By Product Type) South Africa (By Product Type) Rest of the Middle East & Africa (By Product Type)